New drug combo targets rare blood cancers

NCT ID NCT06034002

Recruiting now Disease control Sponsor: Incyte Corporation Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a new drug called INCA033989, alone or with an existing drug (ruxolitinib), in people with myeloproliferative neoplasms—a group of rare blood cancers that cause the bone marrow to produce too many cells. The study aims to find safe doses and check for side effects in about 290 participants. It is not yet testing whether the drug works, but it is a first step toward a potential new treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: INCA033989 (a drug) and ruxolitinib (also known as Jakafi)
What this could lead to: If successful, this could lead to a new treatment option for people with myeloproliferative neoplasms, potentially improving symptom control and reducing spleen size.
What could go wrong: This is an early Phase 1 trial focused on safety and dosing, not yet on effectiveness. The drug may cause side effects or not work as hoped. Results are preliminary and may not lead to a widely available treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

essential thrombocythemia myelofibrosis Myeloproliferative Disorders myeloproliferative neoplasm primary myelofibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYELOPROLIFERATIVE NEOPLASMS

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

City of Hope Medical Center
RECRUITING

Duarte, California, 91010, United States
Cleveland Clinic
RECRUITING

Cleveland, Ohio, 44195, United States
Dana Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States
Icahn School of Medicine At Mount Sinai
RECRUITING

New York, New York, 10029, United States
Johns Hopkins Hospital
RECRUITING

Baltimore, Maryland, 21287, United States
Md Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States
Stanford Cancer Institute
RECRUITING

Palo Alto, California, 94304, United States
The University of Kansas Cancer Center
RECRUITING

Westwood, Kansas, 66205, United States
University of Miami Health System
RECRUITING

Miami, Florida, 33136, United States
Vanderbilt University Medical Center
RECRUITING

Nashville, Tennessee, 37232, United States
Wake Forest Baptist Medical Center
RECRUITING

Winston-Salem, North Carolina, 27157, United States
Washington University School of Medicine
RECRUITING

St Louis, Missouri, 63108, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.